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Besides commercial clinical research, which predominantly aims at obtaining 
marketing authorization for a new product, non-commercial clinical research re-
sponds to questions that originate from treatment practice. Frequently, medicinal 
products or medical devices that are already approved, or interventional ones, 
e.g. surgical or psychotherapeutic methods are investigated. Because research 
concentrates on the exact application procedures, e.g. the advantages or disad-
vantages of a combination of different cancer therapies, on the identification of 
long-term adverse effects, or on the comparison of two treatment methods, the 
manufacturers of the products often cannot expect economic gains from such 
studies. In this case, a non-commercial institution, frequently the medical faculty 
of a university, assumes responsibility for the study (that means, it becomes the 
»sponsor« of the study), and financial support is at least partially needed from 
public funds (from the university’s budget or project funding), or from non-prof-
it foundations. This kind of studies is called non-commercial clinical studies, 
investigator-driven trials (IDCTs) or investigator-initiated clinical trials (IITs), 
partially also as therapy-optimization studies.
Like all clinical studies, the non-commercial trials are regulated by the German 
Drug Law (»Arzneimittelgesetz«, AMG), as long as they analyse the efficacy, 
safety or metabolization of medicinal products, with the objective of testing 
their harmlessness or effectiveness, and if they include a comparison with a con-
trol group or a second treatment condition. This kind of clinical study is referred 
to as clinical trial (»Klinische Prüfung«).
The present report describes and evaluates the manifold factors which contrib-
ute to powerful non-commercial clinical research in Germany, and makes sug-
gestions to further optimize the framework conditions. To this end, the medical 
faculties in Germany were surveyed and expert interviews as well as a final 
workshop were carried out.
The delineation of non-commercial and commercial clinical studies is not always 
trivial. It is, however, necessary when the governmental agencies have to decide 
about reducing or waiving the fees that have to be paid for the authorization of 
a trial, or if funding from public means is requested. An important criterion is 
the for-profit orientation of the sponsor and, related to that, the scientific aim 
of the study. This can be inferred among other factors from whether the data 
and results of the study can be published freely or if a company exerts influence 
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on the publication. In non-commercial studies, the substance being researched 
frequently already has marketing approval for the investigated indication group. 
The funding of the study, however, is often not an unequivocal criterion, because 
mixed financial support from companies as well as public funds is frequent. In 
addition, the economic benefit resulting from a study can only be assessed long 
after it has been completed, e.g. if the study led to an extended marketing au-
thorization and thus to an increased market for the investigated product.
Non-commercial studies are indispensable for clinical practice for several rea-
sons. It has been shown that the results of commercial clinical studies are partial-
ly biased towards too positive outcomes, e.g. because studies with positive out-
comes are more frequently published, whereas negative outcomes are suppressed 
(so-called publication bias). Therefore, studies that are independent of the man-
ufacturer are necessary, as control and correction. Furthermore, many questions 
are highly relevant for clinical practice, but do not promise increased revenues 
for the manufacturer, so his motivation to invest in a clinical trial is low. Such 
studies often imply the direct comparison of two or more treatment options (so-
called head-to-head studies), the testing of approved medicines for effectiveness 
in daily clinical routine, or the development of new methods that do not promise 
a lucrative market. Furthermore, there are many therapeutic questions in which 
no medical products are applied at all, e.g. in surgery or psychotherapy, but also 
in lifestyle interventions or in the field of prevention. Whereas the results of such 
studies are highly relevant for health policy or for health insurance companies, 
they are inherently of no commercial interest to a producer.
Non-commercial clinical trials are not only required as thematic complements, 
but also as a correction for commercial studies, which are partially suspected 
of biasing the results in a direction which is unreasonably positive for the spon-
sor, who is mostly the producer of a new pharmaceutical product. Such biases 
emerge, among others, from the fact that the studies predominantly published are 
those that have led to positive results, while negative results could be dropped. 
In order to increase transparency, reduce publication bias and avoid unnecessary 
studies, obligatory and publicly accessible study registries, combined with the 
publication of the study results, are suggested.
The amount of non-commercial clinical research in Germany is in a range sim-
ilar to that in other countries. Its share of all clinical research has not changed 
substantially in the last years, and also no large increase can be expected for the 
future. Four fifths of non-commercial studies at the medical faculties only recruit 
participants from Germany, so that the degree of internationalization is low. 
This distribution also roughly equals the international average.
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Amongst the areas of medicine in which non-commercial studies are carried out, 
haematology/oncology is the strongest. These studies are frequently funded by 
the German Cancer Aid (»Deutsche Krebshilfe«). The second strongest disci-
plines in non-commercial clinical research are neurology/psychiatry/psychology.
In the view of the medical faculties, the financial support for non-commercial 
studies is the most problematic factor. On top of that, the following aspects are 
considered problematical: recruiting study patients, resource-intensive monitor-
ing of the studies, validity of the data, qualification of the personnel, as well as 
problems with supervising authorities and independent ethics committee. To a 
smaller extent, the support in the phase of application for the authorization of a 
trial and patient safety are also regarded as problematic.
Even amongst the non-commercial studies, more than half of the trials are at 
least partially funded by companies. The second most important source of fi-
nancial support is the joint funding programme of the Federal Ministry for Edu-
cation and Research (BMBF) and the German Research Foundation (»Deutsche 
Forschungsgemeinschaft«, DFG), followed by other public funding and univer-
sity funds. Foundations and the European Union (EU) only play a subordinate 
role.
The size of the BMBF and DFG funding programme is considered by the clin-
ical researchers to be far too small. Other sources, e.g. the health insurance 
companies, should also contribute. However, even the funds available in the 
BMBF/DGF programme could not be expended in total, because the quality 
of the research proposals partially did not comply with the programme’s qual-
ity standards. This gives strong evidence of an urgent need for methodological 
support for the researchers and improving their qualifications. The research in-
frastructure provided by the Coordination Centres for Clinical Studies (»Koor-
dinierungszentren für Klinische Studien«, KKS) is regarded as very supportive; 
however, it is not available in all regions and needs additional flanking measures.
The regulations for clinical trials are still considered resource-consuming and 
partially prohibitive. Nationally and internationally, approaches are tested to 
graduate the requirements according to the risk for the study participants. In this 
context, in Germany, the BMBF is funding the ADAMON study. The results of 
this study, together with the researchers, should be used to establish criteria for 
the requirements for studies and eventually reduced fees and premiums for par-
ticipants’ insurance. Simplifications for studies with already approved drugs are 
already in place. This could be supported by an even more stringent implementa-
tion of the guidelines for ethical review boards. Compromises regarding patient 
4
SUMMARY
safety or the study quality should not be made, because despite the considerable 
efforts required, it is these two aspects in particular that are important assets of 
clinical research in Germany.
Clear criteria should also be established for the public benefit that is expected 
from a publicly funded study; these criteria should also be used for funding 
decisions. They could contribute to a more transparent procedure by which the 
Federal Joint Committee (»Gemeinsamer Bundesausschuss«, GBA) decides on 
the reimbursement of treatment costs for study patients by the statutory health 
insurance companies.
The at least partial funding of non-commercial clinical trials by companies is 
generally regarded as necessary and unproblematic in its implementation. In 
order to invest the resources for non-commercial clinical trials from the public 
as well as from private sources in a more targeted way, a joint fund for clinical 
studies should be discussed, to which the public, private funders, foundations, 
as well as service providers and insurance companies must contribute and which 
decides about the funding of projects according to the aforementioned criteria. 
Such an institution which should be guided by the societal need for research in 
specific fields, could also advise in the better integration of clinical research into 
broader health research, e.g. the coordination of funding decisions in Interdis-
ciplinary Centres for Clinical Research (»Interdisziplinäre Zentren für Klinische 
Forschung«, IZKF), the clinical study centres (»Klinische Studienzentren«) or 
the integrated research and treatment centres.
In addition, funding and other support should be extended to more non-uni-
versity hospitals and outpatient care. As recruiting study participants is still a 
problem, this should lead to an increase in potential study centres, facilitate the 
networking between centres and thus improve the patients’ access to studies. To 
this end, however, it is also necessary that clinical professionals are motivated 
and qualified for research. A higher value placed on clinical research activities in 
staff selection and in post offerings – as opposed to the actual focus on basic re-
search – combined with better training, could improve the personnel situation. A 
generally increased esteem for clinical research in society would also contribute 
to more patients volunteering to participate in a study. This should be supported 
by appropriate information for the public.
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